Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on January 25, 2024, that the U.S. Patent and Trademark Office (USPTO) has granted a new patent for Talicia, their treatment for Helicobacter pylori (H. pylori) infection. The patent, U.S. Patent No. 11,878,011, covers the use of Talicia as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) and extends its protection until May 2042. This development is significant as obesity rates in the U.S. continue to climb, and obesity has been linked to the failure of other H. pylori treatments. Talicia, which is a combination of two antibiotics and a proton pump inhibitor, is the leading branded first-line therapy for H. pylori prescribed by U.S. gastroenterologists. The drug is also eligible for eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is protected by additional patents extending until 2034, with further patents pending worldwide.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on January 25, 2024, that the U.S. Patent and Trademark Office (USPTO) has granted a new patent for Talicia, their treatment for Helicobacter pylori (H. pylori) infection. The patent, U.S. Patent No. 11,878,011, covers the use of Talicia as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) and extends its protection until May 2042. This development is significant as obesity rates in the U.S. continue to climb, and obesity has been linked to the failure of other H. pylori treatments. Talicia, which is a combination of two antibiotics and a proton pump inhibitor, is the leading branded first-line therapy for H. pylori prescribed by U.S. gastroenterologists. The drug is also eligible for eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is protected by additional patents extending until 2034, with further patents pending worldwide.
专业生物制药公司RedHill Biopharma Ltd. 于2024年1月25日宣布，美国专利商标局（USPTO）已为其治疗幽门螺杆菌（H. pylori）感染的塔利西亚授予了一项新专利。该专利，美国专利号为11,878,011，涵盖了使用塔利西亚作为根除幽门螺杆菌的方法，无论患者体重指数（BMI）如何，并将其保护期延长至2042年5月。随着美国肥胖率的持续攀升，这一发展意义重大，肥胖与其他幽门螺杆菌治疗的失败有关。塔利西亚结合了两种抗生素和一种质子泵抑制剂，是美国胃肠病学家开的领先品牌幽门螺杆菌一线疗法。该药物凭借其合格传染病产品称号，还有资格在美国市场独家经营八年，并受延期至2034年的其他专利保护，全球还有更多专利正在申请中。
专业生物制药公司RedHill Biopharma Ltd. 于2024年1月25日宣布，美国专利商标局（USPTO）已为其治疗幽门螺杆菌（H. pylori）感染的塔利西亚授予了一项新专利。该专利，美国专利号为11,878,011，涵盖了使用塔利西亚作为根除幽门螺杆菌的方法，无论患者体重指数（BMI）如何，并将其保护期延长至2042年5月。随着美国肥胖率的持续攀升，这一发展意义重大，肥胖与其他幽门螺杆菌治疗的失败有关。塔利西亚结合了两种抗生素和一种质子泵抑制剂，是美国胃肠病学家开的领先品牌幽门螺杆菌一线疗法。该药物凭借其合格传染病产品称号，还有资格在美国市场独家经营八年，并受延期至2034年的其他专利保护，全球还有更多专利正在申请中。
有用
没用